The first phase of the study aims to remove these plaques in cognitively impaired and unimpaired carriers of the inherited presenilin 1 (PSEN1) E280A mutation, as well as evaluate ways to stave off ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback